Market Segmentation
- Multi Cancer Early Detection Type Outlook (Revenue, USD Million, 2018 - 2030)
- Liquid Biopsy
- Gene Panel, LDT & Others
- Multi Cancer Early Detection End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospitals
- Diagnostic Laboratories
- Others
- Multi Cancer Early Detection Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- North America Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- North America Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- U.S.
- U.S. Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- U.S. Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Canada
- Canada Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Canada Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Europe
- Europe Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Europe Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Germany
- Germany Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Germany Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- U.K.
- U.K. Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- U.K. Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- France
- France Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- France Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Italy
- Italy Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Italy Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Spain
- Spain Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Spain Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Asia Pacific
- Asia Pacific Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Asia Pacific Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Japan
- Japan Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Japan Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- China
- China Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- China Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- India
- India Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- India Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Australia
- Australia Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Australia Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- South Korea
- South Korea Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- South Korea Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Latin America
- Latin America Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Latin America Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Brazil
- Brazil Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Brazil Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Mexico
- Mexico Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Mexico Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Argentina
- Argentina Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Argentina Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Middle East and Africa
- Middle East and Africa Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Middle East and Africa Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- South Africa
- South Africa Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- South Africa Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- Saudi Arabia
- Saudi Arabia Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- Saudi Arabia Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
- UAE
- UAE Multi Cancer Early Detection Market, By Type
- Liquid Biopsy
- Gene Panel, LDT, & Others
- UAE Multi Cancer Early Detection Market, By End-use
- Hospitals
- Diagnostic Laboratories
- Others
Multi Cancer Early Detectione Market Dynamics
Driver - Increasing Prevalence Of Cancer
The market is expected to be driven by the rising incidence of numerous malignancies and the growing demand for effective ways to identify them early on so that prompt, suitable treatment can be provided. For example, the International Agency for Research on Cancer (IARC) estimates that in 2023 there will be about 20.7 million new cases of cancer. The necessity for early cancer detection diagnostics to aid with disease management and mortality reduction is expected to drive the industry as a whole. MCED tests are intended to find cancers in the body when a patient is asymptomatic. They assess several signals at the same time to assess if a patient has a high chance of having cancer. Cancer is one of the top causes of mortality worldwide, expected to account for 10 million deaths in 2020 or one in every six people. Factors including alcohol misuse, smoking, obesity, high cholesterol, and body mass index account for one-third of cancer-related fatalities. Cancer is most successfully and efficiently treated when it is discovered early, that is when it is localized before it has spread to other parts of the body.
Driver - Extensive R&D For The Development Of Mced
Currently in the advanced stages of research, the revolutionary MCED screening technique is projected to bring about a substantial breakthrough in cancer screening and care. Molecularly guided excision biopsy (MCED) is the process of detecting malignancies using biomarkers that circulate in human fluids (blood, for example), such as circulating tumor cells and circulating cell-free tumor DNA. This may be the most sophisticated use of the liquid biopsy technique to date (ctDNA). The World Economic Forum has named liquid biopsy as one of the fastest-developing technologies in the world, even though scientists have been attempting to create methods of diagnosing cancer through analysis of blood since the 1960s and are aware that free-floating DNA exists in the blood. Significant breakthroughs in cancer diagnosis and therapy are being made possible by emerging biological and informational technologies, including genome sequencing, big data analytics, nanotechnology, and artificial intelligence/machine learning (AI/ML). The purpose of MCED screening is to expand the number of asymptomatic individuals who can receive a cancer diagnosis as well as the variety of malignancies for which screening techniques are accessible.
Restraint - Collection Of Adequate Safety And Efficacy Data For Regulatory Approval
Despite being a newer development in the market for cancer detection and diagnosis, obtaining regulatory clearance for MCED tests is hampered by the need to gather adequate effectiveness and safety evidence. FDA and NCI, however, are seeking data to investigate and assess MCEDs. The FDA has been discussing whether real-world data should be included in the appraisal of MCED tests and which indication is necessary for approval. To notice the crucial evaluation questions needed to look at the performance characteristics, safety, and clinical outcomes of MCED tests, the organization held a public workshop in March 2020. Conducting clinical screening studies, such as RCTs, to generate the requisite evidence of the clinical validity and effectiveness of MCED screening tests may prove to be logistically challenging. Large enrollment numbers (i.e., on the order of tens of thousands of participants), extensive resourcing, one or more decades of longitudinal follow-up, and an appropriate study design are essential to validate a cancer-specific mortality benefit for individual cancer types across a broad range of cancer types in the intended use population.
What Does This Report Include?
This section will provide insights into the contents included in this multi cancer early detection market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Multi cancer early detection market qualitative analysis
Multi cancer early detection market quantitative analysis
-
Market size, estimates, and forecast from 2018 to 2030
-
Market estimates and forecast for product segments up to 2030
-
Regional market size and forecast for product segments up to 2030
-
Market estimates and forecast for application segments up to 2030
-
Regional market size and forecast for application segments up to 2030
-
Company financial performance